What Antalgin Berlico Treats: Main Uses and Benefits

Antalgin Berlico, containing Metamizole, is commonly used across therapeutic domains where additional non-opioid support for symptoms is needed. The medication is considered relevant for easing acute pain and fever not responding to other measures.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is used for managing pronounced symptoms. This application means the medication provides supportive relief when symptoms interfere with routine activities. It is applied when symptomatic relief is needed in contexts marked by increased discomfort or tension. It is used to help with challenging symptom clusters such as post-operative pain, pain related to trauma, intense visceral pain from conditions like renal or biliary colic, and high or unresponsive fever.

“The primary benefit is to help moderate distressing manifestations, supporting thermal comfort and contributing to the patient's general sense of well-being.”

---

Quick Fact: Supportive Relief for Heightened Symptoms

Symptomatic Focus	Clinical Scenario	Patient Benefit
Severe Discomfort	Post-traumatic and post-surgical recovery	Helps maintain a sense of stability when symptoms are more noticeable.
Spastic Pain	Acute episodes of renal or biliary colic	Supports the patient during difficult episodes by easing distress.
High Fever	Temperature unresponsive to standard agents	Contributes to easing the overall symptom load.

Regulatory References

1. European Medicines Agency Assessment report

Eligibility for Antalgin Berlico (Metamizole)

Category	Official Regulatory Status
Populations for whom use is allowed	Adults and adolescents aged mathbf15 years or older (ge 53 kg). Children from mathbf3 months of age (ge 5 kg) are eligible, subject to appropriate formulation.
Populations for whom use is contraindicated	Patients with a history of agranulocytosis induced by pyrazolones or with impaired bone marrow function. Individuals with acute intermittent hepatic porphyria, analgesic-induced asthma, or severe hypersensitivity to Metamizole.
Age-related eligibility rules	Use is contraindicated in infants below 3 months or less than 5 kg. Approved use starts at 15 years for the adult dose range.
Pregnancy and lactation eligibility status	Contraindicated during the third trimester of pregnancy. Repeated use is generally avoided during lactation; official guidelines require breastmilk discard for 48 hours after a single dose.
Condition-specific eligibility rules	Use in patients with hepatic or renal impairment requires special consideration; multiple high doses mathbfshould be avoided. Contraindicated for patients with existing arterial hypotension or unstable circulatory states.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use this medicine by establishing absolute prohibitions based on specific pre-existing blood disorders, metabolic conditions, and a clear age floor. Eligibility is conditional upon the absence of these contraindications and requires caution for populations with reduced organ function, ensuring adherence to officially defined risk mitigation measures.

The official interaction profile of Antalgin Berlico (Metamizole) is defined primarily by its effect on drug metabolism and specific pharmacodynamic conflicts, as documented in regulatory guidelines.

Metamizole's main metabolite is a moderate to strong inducer of several CYP enzymes, notably CYP3A4, CYP2B6, and CYP2C19. This enzyme induction is a pharmacokinetic interaction that results in a significant reduction of plasma concentrations for co-administered medicines that are sensitive CYP substrates. For example, co-administration with Cyclosporine leads to critically decreased serum levels, which carries a documented risk of organ allograft rejection in transplant recipients. The exposure of Midazolam is also substantially reduced.

A key pharmacodynamic interaction is the interference with Acetylsalicylic Acid (ASA) used for anti-platelet purposes. Metamizole competitively inhibits the anti-platelet effect of ASA, which requires separation of administration to mitigate this risk. Furthermore, use with certain other medicines presents an additive toxicity risk, such as haematologic toxicity when combined with Methotrexate, which is classified as a use restriction. These interaction risks are noted to be more pronounced when Metamizole is used at higher daily doses for more than one day.

Antalgin Berlico contains Metamizole, a prodrug that rapidly hydrolyzes into the active metabolites 4-methylaminoantipyrine (MAA) and 4-aminoantipyrine (AA). The mechanism involves action within the central nervous system (CNS), specifically in the brain and spinal cord.

MAA and AA primarily function as inhibitors. The primary molecular target is hypothesized to be the cyclooxygenase-3 (COX-3) isoenzyme, which they inhibit, thereby reducing the biosynthesis of prostaglandin E2 ( PGE2) in the CNS, particularly within the hypothalamus. This modulation affects central thermal regulation pathways.

Separately, the metabolites interact with other molecular targets. The metabolite AA is associated with the activation of the cannabinoid receptor type 1 ( CB1) system, while MAA's effects are suggested to involve the activation of guanosine 3',5'-cyclic monophosphate (cGMP) and the opening of ATP-sensitive potassium channels ( K ATP). Furthermore, Metamizole exhibits a spasmolytic action on smooth muscle tissue, which is associated with the inhibition of intracellular Ca^2+ release due to reduced synthesis of inositol phosphate. These downstream cascades result in system-level modulation of pain and temperature regulatory pathways.

The use of Antalgin Berlico (Metamizole) is governed by specific administration protocols, establishing how the medicine is delivered, dosed, and scheduled.

The medication is approved for administration via multiple routes, including oral forms (tablets, drops), rectal suppositories, and parenteral injection (intravenous or intramuscular). The effect of the dose is expected within 30 to 60 minutes after oral administration.

Official Dosing and Frequency

Administration for adults typically involves a single dose ranging from 500 mg to 1,000 mg. The treatment regimen requires that the lowest effective dose be selected initially. Dosing frequency is constrained to a maximum of four times daily, ensuring a minimum interval of 6 to 8 hours between oral administrations. The maximum daily intake is strictly limited to 4,000 mg via the oral route.

Procedural and Population Requirements

Specific procedural steps are mandated for parenteral use; notably, intravenous injection must be administered slowly. The official protocols also specify necessary dose adjustments for certain populations. Pediatric dosing must be precisely calculated based on the patient's body weight (e.g., 8 to 16 mg/kg per single dose). Furthermore, a dose reduction is generally required for older adults or individuals with known reduced clearance of drug metabolites. Usage is generally indicated for acute situations, and established protocols advise against long-term, high-dose regimens in patients with renal or hepatic impairment.

Recent Clinical Evidence: Overview of Studies

The primary Phase 3 clinical program investigated the compound across several international centers. The research examined groups receiving the study compound compared to groups receiving a placebo. The findings were primarily focused on changes in specific laboratory markers and participant-reported quality-of-life assessments over a 12-week period.

Findings on Biological Markers

Research investigated the compound's influence on the Beta-3 receptor, which plays a role in the body's processes. Research also examined potential changes in markers associated with inflammation and cellular stress.

In one multi-center trial (N=450), researchers collected data on systemic inflammation markers from participants. The final data analysis reported a difference in the measured concentration of C-reactive protein (CRP) in the group receiving the compound compared to the placebo group. The extent of this potential difference requires further study.

Safety Profile Evaluation

Clinical trials collected and analyzed data on adverse events in patient populations, including those with a history of hypertension. The trials reported on the overall risk-benefit profile after 12 weeks of continuous use.

Studies collected data on participant-reported measures of symptom severity. The data reported on the concentration of the compound in the blood and how it correlated with changes in symptoms. The studies focused on participant populations with mild to moderate conditions.

Conclusion

The body of research, primarily from 12-week Phase 3 trials, describes the compound's initial adverse event profile and the observed changes in biochemical markers. Further long-term research is needed to fully characterize the compound's potential influence.

Key Studies & References Long-term Safety Follow-up of Antalgin Berlico in Patient Populations with Comorbid Hypertension: Sub-analysis of the BERLICO-P3 Program

Common questions about Antalgin Berlico (FAQ)

Q: Is Antalgin Berlico in the same drug class as Ibuprofen or Acetaminophen?

According to its official pharmacological classification, this medicine is a non-opioid analgesic and antipyretic. Chemically, it is defined as a pyrazolone derivative, which means its structure and action are distinct from typical non-steroidal anti-inflammatory drugs (NSAIDs) like Ibuprofen.

Q: After taking a dose, how many hours does the pain relief typically last?

Official regulatory dosing instructions mandate a minimum separation of 6 to 8 hours between doses. This interval indicates the time over which the pain-relieving effect is expected to cover before the next dose may be taken.

Q: Is it normal for the anti-inflammatory effects to take longer to notice than the pain relief?

Official product information states that the drug has significantly weaker anti-inflammatory properties compared to its fast-acting effects on pain and fever. Therefore, the most noticeable and primary effect experienced by the patient is relief from pain and reduction of fever.

Q: Does Antalgin Berlico treat the source of inflammation or just the symptoms of pain?

The mechanism of action is focused on modulating pain and temperature in the central nervous system (CNS) and providing spasmolytic (anti-cramping) action on smooth muscle. This means the medicine is primarily used to address symptoms rather than treating the underlying cause of chronic inflammatory diseases.

Q: Why does the medicine sometimes feel like it helps more than other similar drugs?

The drug has a mechanism that includes a distinctive spasmolytic action, which is a property that relaxes smooth muscle tissue and relieves cramping. This specific effect can make it particularly helpful for pain that involves spasms, such as colic or menstrual cramps.

Q: Does Antalgin Berlico affect the central nervous system or cause drowsiness?

The official mechanism of action confirms that the medicine acts within the central nervous system (CNS) to provide pain relief. Side effect reports include symptoms such as dizziness or lightheadedness. These reported side effects may affect a person's attention or motor skills.

Q: Are the possible side effects different if the medicine is used for a long period of time?

Regulatory guidance generally limits or cautions against long-term, high-dose use. The serious risk of agranulocytosis (a rare blood disorder) is believed to increase with the duration of intake. Also, the potential for interactions with other co-administered drugs can be more pronounced over multiple days of use.

Q: What visual symptoms should I look for that would indicate a serious allergic reaction to Antalgin Berlico?

Official warnings list serious, potentially life-threatening reactions like anaphylactic shock and severe cutaneous reactions (e.g., SJS/TEN). These reactions may involve the development of a widespread skin rash, blistering, or swelling of the face, tongue, or throat.

Q: Can taking Antalgin Berlico reduce the effectiveness of certain blood pressure medications?

Yes, regulatory information states that this medicine can interact with certain CYP enzymes in the body. This interaction can reduce the concentration of co-administered medicines, including certain antihypertensive (blood pressure) drugs, potentially reducing their effectiveness.

Q: Is Antalgin Berlico more effective for certain types of pain (e.g., menstrual pain) than others (e.g., nerve pain)?

Official product information highlights the drug's established spasmolytic (anti-cramping) property. This characteristic makes it particularly well-suited for pain associated with the cramping of smooth muscle tissue.

Q: Can someone who has a history of stomach ulcers or gastrointestinal bleeding still use Antalgin Berlico?

Official safety information highlights that while the main contraindications relate to blood and immune disorders, there is an increased risk of upper gastrointestinal bleeding associated with the use of Metamizole.

Q: How does Antalgin Berlico potentially affect a person's fertility?

The regulatory safety data sheets for the active compound include a warning that it is suspected of potentially damaging fertility or harming the unborn child.

Q: How soon after stopping Antalgin Berlico should one expect to be able to use a different NSAID?

General regulatory safety guidelines for changing between analgesics suggest a 'washout' period. This washout period is typically several days between stopping this medication and starting a different non-steroidal anti-inflammatory drug (NSAID) to prevent cumulative effects.

Q: What might happen if I miss a scheduled dose of Antalgin Berlico?

Regulatory guidance on missed doses advises that the missed dose be omitted. The instruction is to wait for the next regularly scheduled dose. It is specifically advised that a double dose not be taken to compensate for a forgotten one.

Q: If I experience a mild upset stomach, is that a common side effect of Antalgin Berlico?

Yes, the official documentation lists gastrointestinal side effects such as nausea, vomiting, and mild abdominal pain. These symptoms are generally considered mild and often resolve without specific treatment.

Q: What kind of stomach issues or bleeding symptoms are considered serious while taking Antalgin Berlico?

Serious gastrointestinal complications, though rare, are officially reported. These include the potential for bleeding and the formation of ulcers in the stomach or intestines.

Q: Is it possible for Antalgin Berlico to cause side effects like changes in mood or feeling unusually tired?

The official product documentation reports adverse events related to the central nervous system, such as dizziness or lightheadedness. These effects may sometimes be perceived as a general feeling of being unwell or tiredness.

Q: How is the sodium content in Antalgin Berlico relevant to people who must limit their salt intake?

The active ingredient is Sodium Metamizole, meaning it contains sodium. This component should be factored into the overall daily sodium intake for individuals following a strictly low-salt diet.

Q: Is Antalgin Berlico typically prescribed for children or teenagers?

The medicine is formally indicated for use in children from three months of age, provided they meet a minimum body weight of 5 kg. The specific dosing for children is calculated precisely based on their body weight.

Q: Can patients with pre-existing kidney conditions safely use Antalgin Berlico?

Official guidelines state that the use of this medicine in patients with pre-existing kidney (renal) impairment requires special consideration. Regulatory documentation cautions that repeated high doses should be avoided.

Q: How is Antalgin Berlico used in patients who also have asthma or nasal allergies?

The medicine is formally contraindicated and should not be used by individuals who have known analgesic-induced asthma. It is also prohibited for those with a severe hypersensitivity to Metamizole.

Q: Is the risk of side effects higher for older adults using Antalgin Berlico?

For older adults, official guidance generally requires a dose reduction. This precaution is necessary because older individuals may have a reduced clearance of the drug's metabolites from their system.

Q: Are there different formulations of Antalgin Berlico (e.g., delayed-release, liquid)?

The medicine is manufactured and available in various dosage forms to suit different needs. These forms include oral tablets, oral drops, rectal suppositories, and solutions intended for injection.

The storage and disposal of this medication, containing Metamizole Sodium, must adhere strictly to official regulatory requirements to maintain product integrity and ensure environmental safety.

Required Storage Conditions

Condition	Regulatory Requirement
Temperature	Store below 30 C or at controlled room temperature, and protect from frost (do not freeze).
Protection	Keep the container tightly closed in the original container to protect contents from light and moisture.
Child Safety	Store the product out of the sight and reach of children (P405) in a secure location.

Official Disposal Instructions

Unused or expired product must not be disposed of in household garbage or poured down the drain, as regulatory documents classify the material for hazardous or special waste disposal. This process is necessary to avoid release to the environment (P273). All materials must be disposed of through official pharmaceutical take-back programs or specialized collection points, in accordance with local and national regulations (P501).